| Literature DB >> 31234877 |
Stefano Rossi1,2, Monia Savi3, Marta Mazzola1,4, Silvana Pinelli1,2, Rossella Alinovi1,2, Laura Gennaccaro5,6,7, Alessandra Pagliaro5,6, Viviana Meraviglia5,6, Maricla Galetti1,2, Omar Lozano-Garcia8,9, Alessandra Rossini5,6, Caterina Frati1, Angela Falco1, Federico Quaini1, Leonardo Bocchi3, Donatella Stilli3, Stéphane Lucas8, Matteo Goldoni1,2, Emilio Macchi2,3, Antonio Mutti1,2,10, Michele Miragoli11,12,13.
Abstract
BACKGROUND: Non-communicable diseases, intended as the results of a combination of inherited, environmental and biological factors, kill 40 million <span class="Species">people each year, equivalent to roughly 70% of all premature deaths globally. The possibility that manufactured nanoparticles (NPs) may affect cardiac performance, has led to recognize NPs-exposure not only as a major Public Health concern, but also as an occupational hazard. In volunteers, NPs-exposure is problematic to quantify. We recently found that inhaled titanium dioxide NPs, one of the most produced engineered nanomaterials, acutely increased cardiac excitability and promoted arrhythmogenesis in normotensive rats by a direct interaction with cardiac cells. We hypothesized that such scenario can be exacerbated by latent cardiovascular disorders such as hypertension.Entities:
Keywords: Arrhythmias; Cardiac electrophysiology; Cardiac fibrosis; Nanotoxicology; Titanium dioxide nanoparticles
Mesh:
Substances:
Year: 2019 PMID: 31234877 PMCID: PMC6591966 DOI: 10.1186/s12989-019-0311-7
Source DB: PubMed Journal: Part Fibre Toxicol ISSN: 1743-8977 Impact factor: 9.400
Fig. 1Study population and experimental protocol. Flowchart describing the number of animals subjected to the different experimental procedures before and after intra-tracheal instillation of saline solution (CTRL group) or saline solution added with TiO2, at a final concentration of 2 mg/kg (TiO2-NP group). * timepoints for oxidative stress and inflammation; § timepoints for real-time PCR analysis; # timepoints for PIXE. For more details see “Outline of the experimental protocols” section
Fig. 2Electrocardiographic waveform and interval durations. Basic electrophysiological parameters evaluated in CTRL (triangles) and TiO2-NPs treated (square) animals. a P wave duration (ms). b PQ segment duration (ms). c QRS complex duration (ms). d RR interval duration (ms). e QTc duration (ms). Kruskal-Wallis (post hoc analyses: Dunn’s multiple comparison) was performed and statistical significance was set at p < 0.05. * vs corresponding 1° week; # vs corresponding 3° week. Data are represented as median and interquartile range (IQR)
Fig. 3Heart rate variability indexes and arrhythmia evaluation. Heart rate variability parameters and spontaneous arrhythmic events in CTRL (triangles) and TiO2-NP (square) groups. a SDRR duration (ms). b r-MSSD duration (ms). c Sinus pauses (SP, number of events). d Atrio-ventricular blocks (AV block, number of events). Kruskal-Wallis (post hoc analyses: Dunn’s multiple comparison’s) was performed and statistical significance was set at p < 0.05. ● vs CTRL; * vs corresponding 1° week; # vs corresponding 3° week; § vs corresponding 6° week. Data are represented as median and IQR
Hemodynamic study
| CTRL ( | TiO2-NP ( | |
|---|---|---|
| Heart rate (beats/min) | 188 ± 5 | 190 ± 5 |
| Systolic arterial BP (mmHg) | 197.5 ± 2.12 | 198.16 ± 7.08 |
| Diastolic arterial BP (mmHg) | 122.4 ± 4.36 | 123.0 ± 4.92 |
| LVSP (mmHg) | 195.9 ± 2.90 | 195.4 ± 5.96 |
| LVEDP (mmHg) | 6.51 ± 0.55 | 8.32 ± 0.64* |
| +dP/dtmax (mmHg/s) | 9639.6 ± 86.37 | 8190.1 ± 264.5* |
| -dP/dtmax (mmHg/s) | − 7790.6 ± 117.7 | − 6608.2 ± 91.28* |
| IVCT (s) | 0.020 ± 0.0002 | 0.022 ± 0.0003* |
Values are means ± standard error of the mean (SEM)
Hemodynamic measurements were performed at 7th week, before sacrifice. Unpaired Student’s t-test
BP blood pressure, LVSP left ventricular systolic pressure, LVEDP left ventricular end-diastolic pressure, +dP/dt maximal rate of left ventricular (LV) pressure rise, −dP/dt maximal rate of LV pressure decline, IVCT isovolumic contraction time
*p < 0.05 vs CTRL
Fig. 4Cardiac refractoriness, excitability, anisotropic conduction velocities and arrhythmia induction. Electrophysiological parameters and the index of arrhythmia inducibility in CTRL (triangles) and TiO2-NPs treated (squares) animals. a Effective refractory period (ERP, ms). b Rheobase (μA). c Chronaxie (ms). d Threshold intensity for a 1 ms duration impulse (μA). e ventricular conduction velocities along fiber (CVl, m/s). f ventricular conduction velocities across fiber (CVt, m/s). g ventricular conduction velocities ratio (CVl/CVt). Kruskal-Wallis (post hoc analyses: Dunn’s multiple comparison) was performed and statistical significance was set at p < 0.05. ● vs CTRL; * vs corresponding 1° week; # vs corresponding 3° week; § vs corresponding 6° week. Data are represented as median and interquartile range (IQR)
Tibial length, cardiac anatomy and morphometric analysis
| CTRL ( | TiO2-NP ( | |
|---|---|---|
| Tibial length (mm) | 38.2 ± 0.95 | 35.7 ± 0.25 * |
| BW (g) | 359.3 ± 6.47 | 356.1 ± 5.70 |
| LVW (mg) | 1200 ± 25.50 | 1119.13 ± 27.91 * |
| LVW/BW (mg/g) | 3.39 ± 0.10 | 3.16 ± 0.11 |
| LV mass (mm3) | 1132.1 ± 24.06 | 1055.8 ± 26.33 * |
| LV wall thickness (mm) | 2.28 ± 0.09 | 2.26 ± 0.06 |
| LV chamber diameter (mm) | 7.43 ± 0.40 | 7.68 ± 0.25 |
| LV chamber length (mm) | 15.44 ± 0.50 | 15.11 ± 0.42 |
| LV chamber volume (mm3) | 361.3 ± 38.16 | 469.3 ± 31.29 * |
| LV mass/chamber volume | 3.11 ± 0.33 | 2.39 ± 0.16 |
| Total fibrosis (%) | 7.64 ± 1.11 | 15.44 ± 3.09 * |
| Diffuse Fibrosis (%) | 4.24 ± 0.82 | 11.69 ± 3.18 * |
| Perivascular Fibrosis (%) | 3.59 ± 0.49 | 4.69 ± 0.45 |
Values are means ± SEM
Unpaired Student’s t-test
BW body weight measured before sacrifice, LV left ventricular, LVW left ventricular weight
*p < 0.05 vs CTRL
Fig. 5Cardiac tissue fibrosis evaluation. Masson’s trichrome staining sections were analyzed by optical microscopy to evaluate perivascular and interstitial fibrosis in the LV myocardium (greenish). Representative images of heart sections from control (a and b) and TiO2-NP treated animals (c and d). a CTRL LV myocardium; black rectangle area is shown at higher magnification in panel (b). c TiO2-NPs treated LV myocardium; black rectangle area is shown at higher magnification in panel (d). Scale bars: a and c = 200 μm; b and d = 100 μm
Fig. 6Ultrastructural features of the alveolar lung parenchyma from a representative untreated CTRL and TiO2-NPs treated SHR. a a type I pneumocyte (PI) and three capillaries (*) are present in the alveolar septum separating air spaces (As) in CTRL lung. b several TiO2-NPs are present in the cytoplasm of a large alveolar macrophage showing, in addition to vacuoles and microvescicles, onionskin-like multimembrane ultrastructures suggestive of autophagy. The area inscribed by white rectangle is shown at higher magnification in the inset. c an aggregate of electrondense TiO2-NPs is located nearby an endothelial cell lining the lumen of a capillary recognizable by the red blood cell (RBC). The white rectangle inscribes an area shown at higher magnification in d to document that TiO2-NPs are not yet internalized. e internalization of TiO2-NPs in a capillary endothelial cell that is better appreciable at higher magnification in (f). Scale Bars: a 5 μm, b, c, e: 2 μm, d, f: 500 nm
Fig. 7TEM analysis of the heart from a representative untreated CTRL and TiO2-NP treated SHR. a low magnification image of a CTRL heart to illustrate the sarcolemma (arrowheads) lining the surface and gap junctions (arrows) delimiting cardiomyocytes filled of mitochondria and myofibrils. On the left, collagen bundles (Col) are present in the interstitial space between an endothelial cell (Ec) lining a capillary lumen (L) and cardiomyocytes. N: cardiomyocyte nucleus. b aggregates of TiO2-NPs within the cardiomyocyte cytoplasm showing effaced myofibrils and swollen mitochondria. c the white rectangle inscribes an area shown at higher magnification in (d) in which the arrowhead points to NP located in the interstitial space between the vessel wall inscribing a lumen (L) and cardiomyocytes (CM). e low magnification image of a treated SHR myocardium to illustrate widening of the interstitial space by abundant fibrotic deposition (Col) surrounding cardiomyocytes (CM) and an endothelial cell (Ec) lining a capillary. Arrowheads point to gap junctions delimiting two CMs. The white rectangle inscribes an area shown at higher magnification in f to document the internalization of TiO2-NP located in proximity of the CM sarcolemma bordered by collagen bundles (Col). Scale Bars: A, C, E: 5 μm, B: 2 μm, D: 1 μm, F: 500 nm
Fig. 8Inflammation and toxicological markers in the heart tissue. Lipid peroxidation products and different inflammatory and toxicological markers evaluated in CTRL (white bars) and TiO2-NPs treated (black bars) animals. a TBARS evaluation in the heart tissue. b IL-6 evaluation in the heart tissue r. c MCP-1 evaluation in the heart tissue. d TIMP-1 evaluation in the heart tissue. Two-way ANOVA (post hoc analyses: Bonferroni test) was performed and statistical significance was set at p < 0.05. ● vs CTRL; * vs corresponding 1° week; # vs corresponding 3° week. Data are represented as mean ± SEM
Fig. 9Molecular analysis displaying different gene expression linked to fibrosis deposition. Graph of different gene expression in CRTL (triangles) and TiO2-NPs treated (square) animals. a ACTA2 gene expression; b COL1A2 gene expression; c COL3A1 gene expression; d COL4A1 gene expression; e TGF-β1 gene expression; f CTGF gene expression. Kruskal-Wallis (post hoc analyses: Dunn’s multiple comparison) was performed and statistical significance was set at p < 0.05. ● vs CTRL; * vs corresponding 1° week; # vs corresponding 3° week. Data are represented as median and IQR